Table 3 Correlation between lymph node metastasis and clinicopathological features in cT1N0M0 breast cancer patients undergoing SLNB
From: Prediction of lymph node metastasis by tumor-infiltrating lymphocytes in T1 breast cancer
Parameters | All intrinsic subtype (n = 319) | HR + HER2-BC (n = 255) | HR + HER2 + BC (n = 10) | HER2enriched BC (n = 14) | TNBC (n = 40) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
pN0 or 1mic (n = 273) | pN1a or 2 (n = 46) | p value | pN0 or 1mic (n = 217) | pN1a or 2 (n = 38) | p value | pN0 (n = 9) | pN1a or 2 (n = 1) | p value | pN0 (n = 11) | pN1a or 2 (n = 3) | p value | pN0 (n = 36) | pN1a or 2 (n = 4) | p value | |
Age (years old) | |||||||||||||||
  ≤ 60 | 158 (57.9%) | 21 (45.7%) | 0.124 | 130 (59.9%) | 17 (44.7%) | 0.081 | 5 (55.6%) | 1 (100.0%) | 0.389 | 7 (63.6%) | 2 (66.7%) | 0.923 | 16 (44.4%) | 1 (25.0%) | 0.455 |
  > 60 | 115 (42.1%) | 25 (54.3%) | 87 (40.1%) | 21 (55.3%) | 4 (44.4%) | 0.(0.0%) | 4 (36.4%) | 1 (33.3%) | 20 (55.6%) | 3 (75.0%) | |||||
Tumor size (mm) | |||||||||||||||
  ≤ 10.0 | 54 (19.8%) | 3 (6.5%) | 0.017 | 45 (20.7%) | 3 (7.9%) | 0.062 | 2 (22.2%) | 0 (0.0%) | 0.598 | 0 (0.0%) | 0 (0.0%) | 1.000 | 7 (19.4%) | 0 (0.0%) | 0.332 |
  > 10.0 | 219 (80.2%) | 43 (93.5%) | 172 (79.3%) | 35 (92.1%) | 7 (77.8%) | 1 (100.0%) | 11 (100.0%) | 3 (100.0%) | 29 (80.6%) | 4 (100.0%) | |||||
Estrogen receptor | |||||||||||||||
 Negative | 50 (18.3%) | 7 (15.2%) | 0.606 | 3 (1.4%) | 0 (0.0%) | 0.466 | 0 (0.0%) | 0 (0.0%) | 1.000 | – | – |  | – | – |  |
 Positive | 223 (81.7%) | 39 (84.8%) | 214 (98.6%) | 38 (100.0%) | 9 (100.0%) | 1 (100.0%) | – | – | – | – | |||||
Progesterone receptor | |||||||||||||||
 Negative | 109 (39.9%) | 16 (34.8%) | 0.506 | 58 (26.7%) | 9 (23.7%) | 0.694 | 4 (44.4%) | 0 (0.0%) | 0.389 | – | – |  | – | – |  |
 Positive | 164 (60.1%) | 30 (65.2%) | 159 (73.3%) | 29 (76.3%) | 5 (55.6%) | 1 (100.0%) | – | – | – | – | |||||
Hormone receptor | |||||||||||||||
 Negative | 47 (17.2%) | 7 (15.2%) | 0.735 | – | – |  | – | – |  | – | – |  | – | – |  |
 Positive | 226 (82.8%) | 39 (84.8%) | – | – | – | – | – | – | – | – | |||||
HER2 | |||||||||||||||
 Negative | 253 (92.7%) | 42 (91.3%) | 0.749 | – | – |  | – | – |  | – | – |  | – | – |  |
 Positive | 20 (7.3%) | 4 (8.7%) | – | – | – | – | – | – | – | – | |||||
Ki67 | |||||||||||||||
  ≤ 14% | 166 (60.8%) | 30 (65.2%) | 0.567 | 148 (68.2%) | 28 (73.7%) | 0.500 | 3 (33.3%) | 0 (0.0%) | 0.490 | 1 (9.1%) | 0 (0.0%) | 0.588 | 22 (61.1%) | 2 (50.0%) | 0.667 |
  > 14% | 107 (39.2%) | 16 (34.8%) | 69 (31.8%) | 10 (26.3%) | 6 (66.7%) | 1 (100.0%) | 10 (90.9%) | 3 (100.0%) | 14 (38.9%) | 2 (50.0%) | |||||
Lymphatic invasion | |||||||||||||||
 ly0 | 201 (73.6%) | 23 (50.0%) | 0.002 | 158 (72.8%) | 20 (52.6%) | 0.012 | 7 (77.8%) | 1 (100.0%) | 0.598 | 8 (72.7%) | 0 (0.0%) | 0.024 | 28 (77.8%) | 2 (50.0%) | 0.224 |
 ly1 | 72 (26.4%) | 23 (50.0%) | 59 (27.2%) | 18 (47.4%) | 2 (22.2%) | 0 (0.0%) | 3 (27.3%) | 3 (100.0%) | 8 (22.2%) | 2 (50.0%) | |||||
Venous invasion | |||||||||||||||
 v0 | 264 (96.7%) | 42 (91.3%) | 0.124 | 209 (96.8%) | 34 (89.5%) | 0.066 | 9 (100.0%) | 1 (100.0%) | 1.000 | 10 (90.9%) | 3 (100.0%) | 0.588 | 36 (100.0%) | 4 (100.0%) | 1.000 |
 v1 | 9 (3.3%) | 4 (8.7%) | 8 (3.7%) | 4 (10.5%) | 0 (0.0%) | 0 (0.0%) | 1 (9.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||||
Nuclear grade | |||||||||||||||
 1, 2 | 243 (89.0%) | 40 (87.0%) | 0.689 | 203 (93.5%) | 35 (92.1%) | 0.742 | 9 (100.0%) | 1 (100.0%) | 1.000 | 7 (63.6%) | 0 (0.0%) | 0.051 | 24 (66.7%) | 4 (100.0%) | 0.168 |
 3 | 30 (11.0%) | 6 (13.0%) | 14 (6.5%) | 3 (7.9%) | 0 (0.0%) | 0 (0.0%) | 4 (36.4%) | 3 (100.0%) | 12 (33.3%) | 0 (0.0%) | |||||
TILs (score) | |||||||||||||||
 0, 1 | 219 (80.2%) | 41 (89.1%) | 0.128 | 190 (87.6%) | 35 (92.1%) | 0.422 | 7 (77.8%) | 1 (100.0%) | 0.598 | 5 (45.5%) | 2 (66.7%) | 0.515 | 17 (47.2%) | 3 (75.0%) | 0.292 |
 2, 3 | 54 (19.8%) | 5 (10.9%) | 27 (12.4%) | 3 (7.9%) | 2 (22.2%) | 0 (0.0%) | 6 (54.5%) | 1 (33.3%) | 19 (52.8%) | 1 (25.0%) | |||||
TILs (score) | |||||||||||||||
 0 | 12 (4.4%) | 13 (28.3%) | < 0.001 | 11 (5.1%) | 11 (28.9%) | < 0.001 | 0 (0.0%) | 0 (0.0%) | 1.000 | 0 (0.0%) | 1 (33.3%) | 0.047 | 1 (2.8%) | 1 (25.0%) | 0.053 |
 1–3 | 261 (95.6%) | 33 (71.7%) | 206 (94.9%) | 27 (71.1%) | 9 (100.0) | 1 (100.0%) | 11 (100.0%) | 2 (66.7%) | 35 (97.2%) | 3 (75.0) | |||||